JP2024504903A - 細胞死が観察される組織において特異的に作用する分子 - Google Patents

細胞死が観察される組織において特異的に作用する分子 Download PDF

Info

Publication number
JP2024504903A
JP2024504903A JP2023533392A JP2023533392A JP2024504903A JP 2024504903 A JP2024504903 A JP 2024504903A JP 2023533392 A JP2023533392 A JP 2023533392A JP 2023533392 A JP2023533392 A JP 2023533392A JP 2024504903 A JP2024504903 A JP 2024504903A
Authority
JP
Japan
Prior art keywords
antigen
binding
antibody
cell
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504903A5 (https=
Inventor
智之 井川
正大 東
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2024504903A publication Critical patent/JP2024504903A/ja
Publication of JP2024504903A5 publication Critical patent/JP2024504903A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023533392A 2021-01-29 2022-01-28 細胞死が観察される組織において特異的に作用する分子 Pending JP2024504903A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2021013586 2021-01-29
JP2021013586 2021-01-29
EP21211440 2021-11-30
EP21211440.9 2021-11-30
EP22151665 2022-01-14
EP22151665.1 2022-01-14
PCT/JP2022/003299 WO2022163809A1 (en) 2021-01-29 2022-01-28 Molecule specifically acting in a tissue where a cell death being observed

Publications (2)

Publication Number Publication Date
JP2024504903A true JP2024504903A (ja) 2024-02-02
JP2024504903A5 JP2024504903A5 (https=) 2025-02-04

Family

ID=82653502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533392A Pending JP2024504903A (ja) 2021-01-29 2022-01-28 細胞死が観察される組織において特異的に作用する分子

Country Status (4)

Country Link
US (1) US20220251166A1 (https=)
EP (1) EP4284835A4 (https=)
JP (1) JP2024504903A (https=)
WO (1) WO2022163809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150672A1 (en) * 2022-02-04 2023-08-10 Duke University Compositions for and methods of treating hematological cancers
CN119731210A (zh) 2022-04-21 2025-03-28 弗朗西斯克里克研究所有限公司 双特异性结合剂
CN119630793A (zh) * 2022-07-28 2025-03-14 中外制药株式会社 在观察到细胞死亡的组织中特异性地起作用的分子
GB202401381D0 (en) 2024-02-02 2024-03-20 Francis Crick Institute Ltd Anti-actin antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105560A1 (ja) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. 抗grp78抗体を有効成分として含む医薬組成物
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
WO2019244973A1 (ja) * 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
JP2022545699A (ja) * 2019-08-26 2022-10-28 グリーン， ツイード テクノロジーズ， インコーポレイテッド マイクロダイヤモンドを含むフッ素含有エラストマー組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AU2018313810B2 (en) * 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
CN116322763A (zh) * 2020-08-27 2023-06-23 学校法人顺天堂 抗切断型突变calr-cd3双特异性抗体及医药组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105560A1 (ja) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. 抗grp78抗体を有効成分として含む医薬組成物
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
WO2019244973A1 (ja) * 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
JP2022545699A (ja) * 2019-08-26 2022-10-28 グリーン， ツイード テクノロジーズ， インコーポレイテッド マイクロダイヤモンドを含むフッ素含有エラストマー組成物

Also Published As

Publication number Publication date
WO2022163809A1 (en) 2022-08-04
US20220251166A1 (en) 2022-08-11
EP4284835A1 (en) 2023-12-06
EP4284835A4 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
JP7432575B2 (ja) 抗原結合ドメインおよび運搬部分を含むポリペプチド
JP7082484B2 (ja) ポリペプチド異種多量体の製造方法
JP2024105621A (ja) 改変された抗体可変領域を含む抗原結合分子
JP7757458B2 (ja) 抗原結合ドメインおよび運搬部分を含むポリペプチド
US20210388087A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
US20220251166A1 (en) Molecule specifically acting in a tissue where a cell death is being observed
JP7686614B2 (ja) 癌の治療に用いるための抗ｃｄ１３７抗原結合分子
WO2024024882A1 (en) Molecule specifically acting in a tissue where a cell death being observed
CN116848141A (zh) 在观察到细胞死亡的组织中特异性作用的分子
HK40092444A (zh) 在观察到细胞死亡的组织中特异性作用的分子
HK40116953A (zh) 在观察到细胞死亡的组织中特异性地起作用的分子
RU2850715C2 (ru) Антигенсвязывающая молекула, содержащая измененную вариабельную область антитела
RU2815452C2 (ru) Полипептид, включающий антигенсвязывающий домен и транспортирующий сегмент
RU2827545C9 (ru) Полипептид, содержащий антигенсвязывающий домен и транспортирующий сегмент
RU2827545C2 (ru) Полипептид, содержащий антигенсвязывающий домен и транспортирующий сегмент
WO2025169945A1 (ja) 安定性が改善されたｃｄ３標的抗原結合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415